The Moderna settlement provides a substantial near-term cash infusion ($178.7M expected in July 2026) and removes a major litigation overhang. Monitor for the contingent $1.3B payment decision and upcoming imdusiran Phase 2b data. The Fast Track designation could accelerate regulatory timelines.
Price Chart
Executive Summary
Arbutus reported Q1 2026 GAAP EPS of $0.87 (diluted), a massive beat vs. consensus of -$0.06, driven by $178.7M in license revenue from the Moderna settlement. Revenue surged to $179.1M from $1.8M YoY, and the company ended the quarter with $95.2M in cash. The stock will move on the magnitude of the settlement cash inflow and the FDA Fast Track designation for imdusiran, though the core business remains pre-revenue.
Key Financial Metrics
Key Facts
- Q1 2026 GAAP diluted EPS $0.87 vs consensus -$0.06 (beat by $0.93)
- Total revenue $179.1M vs $1.8M YoY, driven by $178.7M license revenue from Genevant/Moderna settlement
- Net income $169.7M vs net loss $24.5M YoY
- Cash, cash equivalents and marketable securities $95.2M as of March 31, 2026
- FDA granted Fast Track designation for imdusiran (chronic hepatitis B) in April 2026
- Moderna settlement includes $950M upfront payment (July 2026) plus up to $1.3B contingent payment
- Company expects to receive ~$178.7M of the upfront payment in July 2026
- Operating cash flow used $8.1M in Q1 2026, including restructuring payments
Financial Impact
Q1 revenue of $179.1M (vs $1.8M YoY) driven by $178.7M license revenue; net income of $169.7M vs loss of $24.5M; cash position $95.2M
Risk Factors
- Core business remains pre-revenue; ongoing operating cash burn of ~$8M/quarter
- Contingent $1.3B Moderna payment depends on appellate ruling under 28 U.S.C. §1498
- Imdusiran clinical and regulatory risk; no guarantee of approval
- Restructuring and workforce reduction may impact future R&D capabilities
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293879 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 6w ago | 8-K | $5.21 $5.00 | ▼ −4.03% | ▼ −3.50% | $4.45 (−14.59%) |
Aug 15, 2026 6w ago | Institutional Cluster | $4.71 $5.06 | ▲ +7.43% | ▲ +9.41% | $4.45 (−5.52%) |
Aug 12, 2026 7w ago | 8-K | $4.59 $5.12 | ▲ +11.55% | ▲ +13.44% | $4.45 (−3.05%) |
Aug 12, 2026 7w ago | Press Release | $4.59 $5.12 | ▲ +11.55% | ▲ +13.44% | $4.45 (−3.05%) |
Jul 16, 2026 11w ago | 8-K | $4.74 $4.58 | ▼ −3.38% | ▼ −6.99% | $4.45 (−6.12%) |
Jun 12, 2026 16w ago | Institutional Cluster | $4.26 $4.80 | ▲ +12.68% | ▲ +10.90% | $4.45 (+4.46%) |
May 13, 2026 20w ago | 8-K | $4.31 $4.29 | ▼ −0.46% | ▲ +0.15% | $4.45 (+3.25%) |
May 13, 2026 20w ago | Press Release | $4.31 $4.29 | ▼ −0.46% | ▲ +0.15% | $4.45 (+3.25%) |
Apr 15, 2026 24w ago | 8-K | $4.48 $4.31 | ▼ −3.79% | ▼ −9.84% | $4.45 (−0.67%) |
Mar 23, 2026 27w ago | Press Release | $4.42 $4.43 | ▲ +0.23% | ▼ −7.19% | $4.45 (+0.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access